Shares of Harrow, Inc. (NASDAQ:HROW - Get Free Report) traded up 3.9% during mid-day trading on Thursday . The stock traded as high as $38.17 and last traded at $37.92. 216,793 shares changed hands during trading, a decline of 54% from the average session volume of 473,546 shares. The stock had previously closed at $36.50.
Wall Street Analyst Weigh In
A number of equities research analysts have recently commented on the company. HC Wainwright raised their target price on Harrow from $60.00 to $64.00 and gave the company a "buy" rating in a research report on Wednesday, August 13th. BTIG Research boosted their price objective on Harrow from $62.00 to $63.00 and gave the company a "buy" rating in a research report on Thursday, August 14th. Cantor Fitzgerald started coverage on Harrow in a research note on Friday, July 11th. They set an "overweight" rating and a $76.00 target price for the company. Zacks Research raised shares of Harrow from a "hold" rating to a "strong-buy" rating in a research note on Thursday, August 14th. Finally, William Blair assumed coverage on shares of Harrow in a report on Tuesday, June 10th. They issued an "outperform" rating for the company. One analyst has rated the stock with a Strong Buy rating and seven have assigned a Buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $64.67.
Read Our Latest Research Report on HROW
Harrow Stock Performance
The firm has a fifty day moving average price of $33.48 and a 200 day moving average price of $28.98. The company has a current ratio of 0.62, a quick ratio of 0.58 and a debt-to-equity ratio of 0.78. The firm has a market cap of $1.41 billion, a PE ratio of -152.92 and a beta of 0.41.
Harrow (NASDAQ:HROW - Get Free Report) last issued its earnings results on Monday, August 11th. The company reported $0.24 EPS for the quarter, topping analysts' consensus estimates of $0.01 by $0.23. The company had revenue of $63.74 million for the quarter, compared to the consensus estimate of $64.23 million. Harrow had a negative net margin of 4.49% and a negative return on equity of 2.18%. Harrow has set its FY 2025 guidance at EPS. As a group, equities research analysts expect that Harrow, Inc. will post -0.53 earnings per share for the current fiscal year.
Institutional Trading of Harrow
Several institutional investors and hedge funds have recently bought and sold shares of HROW. GF Fund Management CO. LTD. acquired a new position in shares of Harrow in the 4th quarter worth approximately $25,000. Quarry LP purchased a new stake in Harrow during the 1st quarter worth approximately $32,000. Raymond James Financial Inc. acquired a new stake in shares of Harrow in the second quarter valued at $48,000. Tower Research Capital LLC TRC raised its holdings in shares of Harrow by 769.5% in the 4th quarter. Tower Research Capital LLC TRC now owns 1,652 shares of the company's stock valued at $55,000 after purchasing an additional 1,462 shares in the last quarter. Finally, Aquatic Capital Management LLC acquired a new position in shares of Harrow during the fourth quarter worth $78,000. 72.76% of the stock is currently owned by hedge funds and other institutional investors.
About Harrow
(
Get Free Report)
Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.
Featured Stories
Before you consider Harrow, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Harrow wasn't on the list.
While Harrow currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
